Tyr809
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteprivacy & cookiesCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Phosphorylation Site Page:
Tyr809 - CSFR (human)

Site Information
DIMNDSNyIVKGNAR   SwissProt Entrez-Gene
Predicted information:  Scansite
Orthologous residues: CSFR (mouse): Y807, CSFR (rat): (Y807)
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448365
Additional spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13), mutation of modification site (14, 15, 16, 18, 19, 20), phospho-antibody (14, 15, 19), western blotting (14, 15, 16)
Disease tissue studied: breast cancer (6, 7, 10, 11, 12, 13), leukemia (4, 5), acute myelogenous leukemia (4, 5), lung cancer (8, 9), non-small cell lung cancer (8, 9)
Relevant cell line - cell type - tissue: 32D (myeloid) (14), 3T3 (fibroblast) (15, 16, 18), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] (19), FDCP-1 (myeloid) (20), GDM-1 (myeloid) (5), Jurkat (T lymphocyte) (2), lung (8, 9), MCF-10A (breast cell) (1, 6, 7, 10, 11, 12, 13), MCF-10A (breast cell) [CSFR (human), transfection] (1), NKM-1 (myeloid) (4)

Controlled by
Regulatory protein: CSFR (human) (1)
Putative upstream kinases: CSFR (human) (14)
Kinases, in vitro: CSFR (human) (20)
Treatments: M-CSF (14, 19), SU6656 (14)

Downstream Regulation
Effects of modification on CSFR: activity, induced (14, 20), phosphorylation (15)
Effects of modification on biological processes: cell cycle regulation (20), cell growth, altered (18), transcription, altered (15)


References

1

Knowlton ML, et al. (2010) Profiling Y561-Dependent and -Independent Substrates of CSF-1R in Epithelial Cells. PLoS One 5, e13587
21049007   Curated Info

2

Stokes M (2007) CST Curation Set: 3519; Year: 2007; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Schubert C, et al. (2007) Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors. J Biol Chem 282, 4094-101
17132624   Curated Info

4

Gu T (2005) CST Curation Set: 818; Year: 2005; Biosample/Treatment: cell line, NKM-1/-; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Gu T (2005) CST Curation Set: 893; Year: 2005; Biosample/Treatment: cell line, GDM-1/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Gu T (2005) CST Curation Set: 752; Year: 2005; Biosample/Treatment: cell line, MCF-10A/-; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Gu T (2005) CST Curation Set: 753; Year: 2005; Biosample/Treatment: cell line, MCF-10A/-; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Guo A (2005) CST Curation Set: 746; Year: 2005; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Guo A (2005) CST Curation Set: 692; Year: 2005; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Gu T (2005) CST Curation Set: 583; Year: 2005; Biosample/Treatment: cell line, MCF-10A/su 6656; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Gu T (2005) CST Curation Set: 584; Year: 2005; Biosample/Treatment: cell line, MCF-10A/-; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Gu T (2004) CST Curation Set: 498; Year: 2004; Biosample/Treatment: cell line, MCF-10A/-; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Gu T (2004) CST Curation Set: 499; Year: 2004; Biosample/Treatment: cell line, MCF-10A/-; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Rohde CM, Schrum J, Lee AW (2004) A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation. J Biol Chem 279, 43448-61
15297464   Curated Info

15

Ezashi T, Roberts RM (2004) Regulation of interferon-tau (IFN-tau) gene promoters by growth factors that target the Ets-2 composite enhancer: a possible model for maternal control of IFN-tau production by the conceptus during early pregnancy. Endocrinology 145, 4452-60
15217985   Curated Info

16

Novak U, Nice E, Hamilton JA, Paradiso L (1996) Requirement for Y706 of the murine (or Y708 of the human) CSF-1 receptor for STAT1 activation in response to CSF-1. Oncogene 13, 2607-13
9000134   Curated Info

17

Joos H, et al. (1996) Tyrosine phosphorylation of the juxtamembrane domain of the v-Fms oncogene product is required for its association with a 55-kDa protein. J Biol Chem 271, 24476-81
8798707   Curated Info

18

Rabault B, Roussel MF, Quang CT, Ghysdael J (1996) Phosphorylation of Ets1 regulates the complementation of a CSF-1 receptor impaired in mitogenesis. Oncogene 13, 877-81
8761310   Curated Info

19

Novak U, et al. (1995) Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood 86, 2948-56
7579387   Curated Info

20

Baker DA, Maher J, Roberts IA, Dibb NJ (1994) Evidence that ras and myc mediate the synergy between SCF or M-CSF and other haemopoietic growth factors. Leukemia 8, 1970-81
7526094   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.